514 related articles for article (PubMed ID: 11299809)
21. An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer.
Henriksen KL; Rasmussen BB; Lykkesfeldt AE; Møller S; Ejlertsen B; Mouridsen HT
Acta Oncol; 2009; 48(4):522-31. PubMed ID: 19173092
[TBL] [Abstract][Full Text] [Related]
22. Impact of randomized clinical trial results in the national comprehensive cancer network on the use of tamoxifen after breast surgery for ductal carcinoma in situ.
Yen TW; Kuerer HM; Ottesen RA; Rouse L; Niland JC; Edge SB; Theriault RL; Weeks JC
J Clin Oncol; 2007 Aug; 25(22):3251-8. PubMed ID: 17577019
[TBL] [Abstract][Full Text] [Related]
23. Influence of chemotherapy to hormonal levels in postmenopausal breast cancer patients.
Pribylova O; Springer D; Svobodnik A; Kyr M; Zima T; Petruzelka L
Neoplasma; 2008; 55(4):294-8. PubMed ID: 18505339
[TBL] [Abstract][Full Text] [Related]
24. Effects of oral versus transdermal estrogen on the growth hormone/insulin-like growth factor I axis in younger and older postmenopausal women: a clinical research center study.
Bellantoni MF; Vittone J; Campfield AT; Bass KM; Harman SM; Blackman MR
J Clin Endocrinol Metab; 1996 Aug; 81(8):2848-53. PubMed ID: 8768841
[TBL] [Abstract][Full Text] [Related]
25. Serum HER-2/neu and response to the aromatase inhibitor letrozole versus tamoxifen.
Lipton A; Ali SM; Leitzel K; Demers L; Harvey HA; Chaudri-Ross HA; Brady C; Wyld P; Carney W
J Clin Oncol; 2003 May; 21(10):1967-72. PubMed ID: 12743150
[TBL] [Abstract][Full Text] [Related]
26. Is adjuvant tamoxifen recommended in post-menopausal node-negative breast cancer patients with high estrogen receptor values?
Floiras JL; Hacene K; Turpin F; Spyratos F
Int J Biol Markers; 2000; 15(2):135-8. PubMed ID: 10883886
[TBL] [Abstract][Full Text] [Related]
27. Clinical criteria as predictive factors of response to primary hormone therapy in locally advanced breast cancer.
Tiezzi DG; de Andrade JM; Marana HR; Garieri AP; de Paula Philbert PM
Breast J; 2009; 15(4):333-8. PubMed ID: 19496783
[TBL] [Abstract][Full Text] [Related]
28. Flaxseed alone or in combination with tamoxifen inhibits MCF-7 breast tumor growth in ovariectomized athymic mice with high circulating levels of estrogen.
Chen J; Power KA; Mann J; Cheng A; Thompson LU
Exp Biol Med (Maywood); 2007 Sep; 232(8):1071-80. PubMed ID: 17720953
[TBL] [Abstract][Full Text] [Related]
29. Effect of tamoxifen on plasma insulin-like growth factor I in patients with breast cancer.
Colletti RB; Roberts JD; Devlin JT; Copeland KC
Cancer Res; 1989 Apr; 49(7):1882-4. PubMed ID: 2924327
[TBL] [Abstract][Full Text] [Related]
30. Cyproterone, norethindrone, medroxyprogesterone and levonorgestrel are less potent local human growth hormone and insulin-like growth factor I secretion stimulators than progesterone in human breast cancer explants expressing the estrogen receptor.
Milewicz T; Kolodziejczyk J; Krzysiek J; Basta A; Sztefko K; Kurek S; Stachura J; Gregoraszczuk EL
Gynecol Endocrinol; 2002 Aug; 16(4):319-29. PubMed ID: 12396561
[TBL] [Abstract][Full Text] [Related]
31. Tumor-specific VEGF-A and VEGFR2 in postmenopausal breast cancer patients with long-term follow-up. Implication of a link between VEGF pathway and tamoxifen response.
Rydén L; Stendahl M; Jonsson H; Emdin S; Bengtsson NO; Landberg G
Breast Cancer Res Treat; 2005 Jan; 89(2):135-43. PubMed ID: 15692755
[TBL] [Abstract][Full Text] [Related]
32. Long-term effects of fenretinide, a retinoic acid derivative, on the insulin-like growth factor system in women with early breast cancer.
Decensi A; Johansson H; Miceli R; Mariani L; Camerini T; Cavadini E; Di Mauro MG; Barreca A; Gonzaga AG; Diani S; Sandri MT; De Palo G; Formelli F
Cancer Epidemiol Biomarkers Prev; 2001 Oct; 10(10):1047-53. PubMed ID: 11588130
[TBL] [Abstract][Full Text] [Related]
33. Rationale for sequential tamoxifen and anticancer drugs in adjuvant setting for patients with node- and receptor-positive breast cancer.
Kim R; Tanabe K; Emi M; Uchida Y; Osaki A; Toge T
Int J Oncol; 2005 Apr; 26(4):1025-31. PubMed ID: 15753998
[TBL] [Abstract][Full Text] [Related]
34. Elderly breast cancer patients treated by conservative surgery alone plus adjuvant tamoxifen: fifteen-year results of a prospective study.
Martelli G; Miceli R; Costa A; Coradini D; Zurrida S; Piromalli D; Vetrella G; Greco M
Cancer; 2008 Feb; 112(3):481-8. PubMed ID: 18098268
[TBL] [Abstract][Full Text] [Related]
35. Comparison of gene expression profiles predicting progression in breast cancer patients treated with tamoxifen.
Kok M; Linn SC; Van Laar RK; Jansen MP; van den Berg TM; Delahaye LJ; Glas AM; Peterse JL; Hauptmann M; Foekens JA; Klijn JG; Wessels LF; Van't Veer LJ; Berns EM
Breast Cancer Res Treat; 2009 Jan; 113(2):275-83. PubMed ID: 18311582
[TBL] [Abstract][Full Text] [Related]
36. Fadrozole hydrochloride in postmenopausal patients with metastatic breast carcinoma.
Miller AA; Lipton A; Henderson IC; Navari R; Mulagha MT; Cooper J
Cancer; 1996 Aug; 78(4):789-93. PubMed ID: 8756373
[TBL] [Abstract][Full Text] [Related]
37. Tamoxifen versus control after adjuvant, risk-adapted chemotherapy in postmenopausal, receptor-negative patients with breast cancer: a randomized trial (GABG-IV D-93)--the German Adjuvant Breast Cancer Group.
Kaufmann M; Graf E; Jonat W; Eiermann W; Geberth M; Albert US; Gademann G; Conrad B; Stahl K; von Minckwitz G; Schumacher M;
J Clin Oncol; 2005 Nov; 23(31):7842-8. PubMed ID: 16258087
[TBL] [Abstract][Full Text] [Related]
38. Elevated levels of circulating insulin-like growth factor-I, IGF-binding globulin-3 and testosterone predict hormone-dependent breast cancer in postmenopausal women: a case-control study.
Kahán Z; Gardi J; Nyári T; Földesi I; Hajnal-Papp R; Ormándi K; Lázár G; Thurzó L; Schally AV
Int J Oncol; 2006 Jul; 29(1):193-200. PubMed ID: 16773200
[TBL] [Abstract][Full Text] [Related]
39. Phase I/II trial of all-trans retinoic acid and tamoxifen in patients with advanced breast cancer.
Budd GT; Adamson PC; Gupta M; Homayoun P; Sandstrom SK; Murphy RF; McLain D; Tuason L; Peereboom D; Bukowski RM; Ganapathi R
Clin Cancer Res; 1998 Mar; 4(3):635-42. PubMed ID: 9533531
[TBL] [Abstract][Full Text] [Related]
40. The endocrine response to acute ghrelin administration is blunted in patients with anorexia nervosa, a ghrelin hypersecretory state.
Broglio F; Gianotti L; Destefanis S; Fassino S; Abbate Daga G; Mondelli V; Lanfranco F; Gottero C; Gauna C; Hofland L; Van der Lely AJ; Ghigo E
Clin Endocrinol (Oxf); 2004 May; 60(5):592-9. PubMed ID: 15104562
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]